ICON‘s executive vice president of Business Development Elizabeth Thiele has been appointed as president of the newly specialised service unit.

ICON CEO Peter Gray said the biopharmaceutical industry and regulators are more than ever before using post-marketing studies to demonstrate efficacy and safety, as well as demonstrating the economic value of products.

"Oxford Outcomes has grown to become a leader in its field and brings to ICON a wealth of expertise in the fields of health economics, outcomes research and epidemiology and a strong reputation for excellent client service," Gray said.